Ca209-73L- A Phase 3, Randomized, Open Label Study To Compare Nivolumab Plus Concurrent Chemoradiotherapy (Ccrt) Followed By Nivolumab Plus Ipilimumab Or Nivolumab Plus Ccrt Followed By Nivolumab Vs Ccrt Followed By Durvalumab In Previously Untreated, Loc
Posted Date: Apr 28, 2021
- Investigator: Emily Daugherty
- Specialties: Cancer, Lung Cancer, Oncology
- Type of Study: Drug
The primary purpose of the study is to compare the effectiveness of nivolumab plus concurrent chemoradiotherapy (CCRT) followed by nivolumab plus ipilimumab (Arm A) vs CCRT followed by durvalumab (Arm C) in participants with untreated Locally Advanced Non-small Cell Lung Cancer.
Criteria:
Locally Advanced Stage Iiia, Iiib, Or Iiic Histologically-Confirmed Nsclc, Ecog 0-1, No History Of Organ Transplant, No Prior Thoracic Radiotherapy, Newly Diagnosed And Treatment-Naïve, No Condition That, In The Opinion Of The Investigator Would Preclude The Patient From Adhering To The Protocol Or Would Increase The Risk Associated With Study Participation
Keywords:
Lung Cancer, Nsclc
For More Information:
Uc Cancer Center
513-584-7658
cancer@uchealth.com